Saturday 17 October 2026
Export PPBT’s income statement to Excel — free account
Purple Biotech Ltd. Sponsored ADR
PPBT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 110.2% and free cash flow fell 62.1%, each against the same quarter a year earlier.
1.14
0.09
−7.32%
Follow PPBT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(10.44%) | (123.97%) | (122.85%) | (110.67%) | |
| (8.77%) | (96.63%) | (104.05%) | (100.91%) | ||
ROIC |
(13.86%) | (20,189.71%) | (546.31%) | (290.25%) | |
Return on Tangible Assets |
(67.18%) | (1,179.53%) | (1,129.79%) | (497.62%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(14.48) | (11.79) | (7.31) | (7.15) | |
Free Cash Flow |
(6.60) | (5.66) | (6.80) | (7.76) | |
Capital Expenditures |
0.01 | 0.00 | — | (0.01) | |
| Other line items | |||||
Cash ROIC |
(15.24%) | (29.42%) | (42.26%) | (42.38%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(10.28) | (30.07) | (27.94) | (28.74) | |
Operating CF/Net income |
2.03 | 0.21 | 0.26 | 0.32 | |
Depreciation/Fixed assets |
1.56 | 1.64 | 1.91 | 2.14 | |
Capex/Depreciation |
0.04 | (0.01) | 0.00 | (0.02) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(14.50) | (11.78) | (7.31) | (7.14) | |
Capex per Share |
0.02 | (0.01) | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates